Personal profile
He currently holds three Clinical Excellence Awards (CEAs) and prides himself in developing patient pathways to optimise patient experience and outcomes.
He is a keen innovator and was the first surgeon in Greater Manchester (GM) to perform HoLEP surgery, which many consider to be the gold standard surgical approach to treating prostate enlargement symptoms. The benefits compared to conventional prostate treatments, such as transurethral resection of prostate or TURP, are reduced bleeding, shorter hospital stays, enhanced removal of prostate obstruction, and longer-lasting benefits.
He has presented and spoken about HoLEP on invitation, and chaired a BAUS, the British Association of Urological Surgeons, session on BPH/LUTS, having regularly reviewed submissions to the BAUS Annual General Meeting.
He was the first UK surgeon to carry out a novel circumcision using the latest generation CircCurer device. He has subsequently mentored urologists on this technique and presented his findings nationally. These findings include rapid surgery (under 10 mins), suitability for local anaesthesia, low post-operative pain, and 100% patient cosmetic satisfaction.
Mr Liew performs laser bladder tumour ablation (TULA) under local anaesthetic. This avoids the need for a formal anaesthetic to treat small bladder tumour recurrences and optimise patient experience outcomes. He co-leads the GM TULA service supporting delivery of this service to every local trust in the North West. He contributed to the 2022 Getting it Right First Time (GIRFT) urology guidance for Bladder Cancer.
He developed the stone multidisciplinary team (MDT) in Wigan, Bolton and Salford and is a Key Opinion Leader in Endourology for Richard Wolf, Teleflex and Coloplast.
He is an active researcher, with over 20 publications on a number of topics, including prostate cancer, kidney stone disease and education. He is the Principal Investigator in a number of key international trials. During 2021, he ran the only non-cancer urology trial in the UK.
He received his research doctorate (Doctor of Medicine, MD) from the University of Manchester after an intensive study of kidney cancer chemotherapy resistance mechanisms at the Christie Hospital.
Mr Liew is an Associate Member of the European Association of Urologists Guidelines Panel for Prostate Cancer. These guidelines are the most sited urology guidance worldwide. He also regularly reviews articles for the British Journal of Urology International.
Latterly, he is an accredited Royal College of Surgeons Educational Supervisor. In this capacity he has chaired numerous training sessions, including the North West Annual Stone Course. He is also involved in Antibiotic Stewardship and is an active member within his NHS trust.
